Central Bank Trust Co Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Central Bank Trust Co reduced its stake in Amgen by 2.34% during the most recent quarter end. The investment management company now holds a total of 11,820 shares of Amgen which is valued at $1,979,850 after selling 283 shares in Amgen , the firm said in a disclosure report filed with the SEC on Oct 7, 2016.Amgen makes up approximately 0.56% of Central Bank Trust Co’s portfolio.

Other Hedge Funds, Including , Sadoff Investment Management added AMGN to its portfolio by purchasing 1,317 company shares during the most recent quarter which is valued at $220,598. Amgen makes up approx 0.02% of Sadoff Investment Management’s portfolio.Summit Financial Wealth Advisors reduced its stake in AMGN by selling 489 shares or 20.95% in the most recent quarter. The Hedge Fund company now holds 1,845 shares of AMGN which is valued at $308,558. Amgen makes up approx 0.13% of Summit Financial Wealth Advisors’s portfolio.New England Research Management reduced its stake in AMGN by selling 2,075 shares or 22.22% in the most recent quarter. The Hedge Fund company now holds 7,265 shares of AMGN which is valued at $1,214,999. Amgen makes up approx 1.02% of New England Research Management’s portfolio.North Star Asset Management Inc reduced its stake in AMGN by selling 100 shares or 5.32% in the most recent quarter. The Hedge Fund company now holds 1,781 shares of AMGN which is valued at $297,854. Amgen makes up approx 0.03% of North Star Asset Management Inc’s portfolio. Lvm Capital Management Ltdmi sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 69,845 shares of AMGN which is valued $11,680,878.

Amgen opened for trading at $167.94 and hit $168.1499 on the upside on Friday, eventually ending the session at $167.5, with a gain of 0.36% or 0.6 points. The heightened volatility saw the trading volume jump to 16,79,823 shares. Company has a market cap of $125,350 M.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.